BR112023003815A2 - Uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico - Google Patents

Uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico

Info

Publication number
BR112023003815A2
BR112023003815A2 BR112023003815A BR112023003815A BR112023003815A2 BR 112023003815 A2 BR112023003815 A2 BR 112023003815A2 BR 112023003815 A BR112023003815 A BR 112023003815A BR 112023003815 A BR112023003815 A BR 112023003815A BR 112023003815 A2 BR112023003815 A2 BR 112023003815A2
Authority
BR
Brazil
Prior art keywords
seb
toxin
detoxified
acid molecule
staphylococcal
Prior art date
Application number
BR112023003815A
Other languages
English (en)
Inventor
Martha M Eibl
Haller Günter
Model Nina
Original Assignee
Biomedizinische Forschung & Bio Produkte Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedizinische Forschung & Bio Produkte Ag filed Critical Biomedizinische Forschung & Bio Produkte Ag
Publication of BR112023003815A2 publication Critical patent/BR112023003815A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico. a presente invenção se refere a uma toxina de exotoxina b (seb) estafilocócica desintoxicada que é mutada para compreender pelo menos duas mutações pontuais nas posições de aminoácidos 21 a 25 na sequência da toxina seb seq id no:1, em que as referidas pelo menos duas mutações pontuais compreendem uma deleção de qualquer uma das aa21-22, aa22-23, aa23-24, aa24-25, aa21-23, aa22-24 ou aa23-25, ou em posições de aminoácidos correspondentes em qualquer outra sequência de toxina seb de ocorrência natural que tenha pelo menos 95% de identidade de sequência com a seq id no:1.
BR112023003815A 2020-12-18 2021-11-03 Uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico BR112023003815A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20215489 2020-12-18
PCT/EP2021/080540 WO2022128243A1 (en) 2020-12-18 2021-11-03 Protective staphylococcal exotoxin vaccine

Publications (1)

Publication Number Publication Date
BR112023003815A2 true BR112023003815A2 (pt) 2023-10-24

Family

ID=73855806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003815A BR112023003815A2 (pt) 2020-12-18 2021-11-03 Uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico

Country Status (7)

Country Link
US (1) US20230104241A1 (pt)
EP (1) EP4081534B1 (pt)
JP (1) JP2023512344A (pt)
KR (1) KR20220132641A (pt)
CN (1) CN115427433A (pt)
BR (1) BR112023003815A2 (pt)
WO (1) WO2022128243A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023247747A1 (en) * 2022-06-23 2023-12-28 Biomedizinische Forschung & Bio-Produkte AG Protective staphylococcal exotoxin vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500328A (ja) * 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
AU746372B2 (en) 1998-02-15 2002-04-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel preventives/remedies for immunopathy
EP1461433A1 (en) * 2001-11-26 2004-09-29 U.S. Medical Research Institute of Infectious Diseases Bacterial superantigen vaccines
WO2005023853A1 (ja) * 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性seb改変体およびそれを含むワクチン
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
CN103965302B (zh) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 一种重组超抗原seb突变体,其制备方法及应用
PT3010535T (pt) 2013-06-19 2020-07-03 Integrated Biotherapeutics Inc Péptidos de toxoide derivados de modulina solúvel em fenol, delta toxina, superantigénios e suas fusões
CN103694321B (zh) * 2013-12-09 2015-11-18 重庆原伦生物科技有限公司 金黄色葡萄球菌mSEB突变体及其制备方法和应用

Also Published As

Publication number Publication date
CN115427433A (zh) 2022-12-02
US20230104241A1 (en) 2023-04-06
EP4081534C0 (en) 2023-06-28
EP4081534A1 (en) 2022-11-02
EP4081534B1 (en) 2023-06-28
WO2022128243A1 (en) 2022-06-23
KR20220132641A (ko) 2022-09-30
JP2023512344A (ja) 2023-03-24

Similar Documents

Publication Publication Date Title
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
Zhang et al. Immunoproteomics of extracellular proteins of Chinese virulent strains of Streptococcus suis type 2
Nho et al. Complete genome sequence and immunoproteomic analyses of the bacterial fish pathogen Streptococcus parauberis
BR112023003815A2 (pt) Uma toxina da exotoxina estafilocócica b (seb) desintoxicada, antígeno de vacina protetora e preparação de vacina, é utilizada na prevenção ou tratamento de uma infecção bacteriana expressando superantígeno estafilocócico, método de produção da toxina seb desintoxicada, molécula de ácido nucleico que codifica a toxina seb desintoxicada, célula hospedeira recombinante compreendendo a molécula de ácido nucleico
Ayalew et al. Immunogenicity of Mannheimia haemolytica recombinant outer membrane proteins serotype 1-specific antigen, OmpA, OmpP2, and OmpD15
EP1874806B1 (en) Vaccine against burkholderia infections
TW201643180A (zh) 鮑氏不動桿菌(Acinetobacter baumannii)多胜肽抗原及其抗體以及編碼該抗原之核酸
Currie Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress
Guzmán-Brambila et al. Two outer membrane lipoproteins from Histophilus somni are immunogenic in rabbits and sheep and induce protection against bacterial challenge in mice
Wolfenden et al. Development and evaluation of candidate recombinant Salmonella-vectored Salmonella vaccines
Moitinho-Silva et al. Mycoplasma hyopneumoniae type I signal peptidase: expression and evaluation of its diagnostic potential
KR20200076551A (ko) 마이코플라즈마 폐렴 및 흉막폐렴 예방용 백신 조성물
Tostes et al. Protection elicited by nasal immunization with recombinant pneumococcal surface protein A (rPspA) adjuvanted with whole-cell pertussis vaccine (wP) against co-colonization of mice with Streptococcus pneumoniae
AR123244A1 (es) Vacuna de salmonella para el tratamiento de coronavirus
Guzmán-Brambila et al. LKTA and PlpE small fragments fusion protein protect against Mannheimia haemolytica challenge
Bameri et al. Determination immunogenic property of truncated MrpH. FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis
Luther et al. Elucidation of the DNA sequence of Streptococcus uberis adhesion molecule gene (sua) and detection of sua in strains of Streptococcus uberis isolated from geographically diverse locations
Zhou et al. T-cell proliferation and antitumour activities of a truncated mutant of staphylococcal enterotoxin C2 with decreased cytokine secretion
EP2391640B1 (en) A clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide
Saxena et al. Cloning, sequencing, and in silico characterization of Omp 28 of Salmonella Typhi (strain MTCC 733) to develop r-DNA vaccine for typhoid fever
Namdar et al. Evaluation of the anti-leishmanial effect of recombinant clostridium α-toxin
BRPI1014505A8 (pt) Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir uma proteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos
Lyman et al. Analysis of the HbpA protein from Corynebacterium diphtheriae clinical isolates and identification of a putative hemoglobin-binding site on HbpA
Pereira et al. Antibodies anti-rFilF protein has anti-biofilm activity against carbapenem-resistant Acinetobacter baumannii
Pandey et al. Cloning and immunopotential analysis of Omp 28 of Salmonella Typhimurium for the development of subunit vaccine for poultry salmonellosis